George M. Milne Jr.
At a glance: George M. Milne Jr. is Director at Amylyx Pharmaceuticals (AMLX). Their latest SEC Form 4, filed Oct 7, 2026, reported a sale of $831K. On file: 0 purchase lines ($0) and 1 sale line ($831K).
Disclosed holdings: about $20.5M of AMLX stock: 782,881 shares reported on their latest Form 4 (filed Oct 7, 2026), valued at the Nov 20, 2026 close of $26.13. This counts only AMLX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Amylyx Pharmaceuticals, Inc. (AMLX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
George M. Milne Jr.'s InsiderPrint
6 trades from SEC Form 4 filings, 2021 to 2026, drawn as one fingerprint.
Reading this print: Mostly buys, trading about once a year, typically $220K a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.
- Bump outward: a purchase (5)
- Dent inward: a sale (1)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- John R. SultDirector · VST · 97% match
- Mark T. BehrmanCEO, President · LXU · 97% match
- Adrian T. DillonDirector · HQY · 95% match
- Andrew LabenneCFO · HAPN · 95% match
- Enrique LoresCEO, President · HPQ · 95% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Every purchase since 2021
From the SEC's insider data sets: each open-market buy by George M. Milne Jr., matched to how the stock did over the next 90 days against the S&P 500.
1 of 3 buys beat the S&P 500 (33%), median -2.2% vs. the index. Small sample: treat with care. All insider buys: 46%.
Buys made close together in one stock count once. Price-only returns; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 7SEC | AMLXAmylyx Pharmaceuticals, Inc. | Sell Plan | 30,000782,881 held (−4%) | $27.70 | $831K | -5.7% |
- Sell
Director George M Milne Jr. sold $831K of AMLX at $27.70 — pre-scheduled 10b5-1 plan sale.
Follow George M. Milne Jr.
Get one email when George M. Milne Jr. files a new purchase or sale. Free.
At most one email a day about George M. Milne Jr., plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.